415 related articles for article (PubMed ID: 25455933)
21. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
[TBL] [Abstract][Full Text] [Related]
22. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Kastritis E; Anagnostopoulos A; Roussou M; Toumanidis S; Pamboukas C; Migkou M; Tassidou A; Xilouri I; Delibasi S; Psimenou E; Mellou S; Terpos E; Nanas J; Dimopoulos MA
Haematologica; 2007 Oct; 92(10):1351-8. PubMed ID: 18024372
[TBL] [Abstract][Full Text] [Related]
23. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
[TBL] [Abstract][Full Text] [Related]
24. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
25. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.
Landau H; Lahoud O; Devlin S; Lendvai N; Chung DJ; Dogan A; Landgren CO; Giralt S; Hassoun H
Biol Blood Marrow Transplant; 2020 Jan; 26(1):204-208. PubMed ID: 31446197
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.
Cornell RF; Zhong X; Arce-Lara C; Atallah E; Blust L; Drobyski WR; Fenske TS; Pasquini MC; Rizzo JD; Saber W; Hari PN
Bone Marrow Transplant; 2015 Jul; 50(7):914-7. PubMed ID: 25915809
[TBL] [Abstract][Full Text] [Related]
27. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response.
Hassoun Y; Kharfan-Dabaja MA; Baz R
Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):138-9. PubMed ID: 25732670
[No Abstract] [Full Text] [Related]
29. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Venner CP; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Blood; 2012 May; 119(19):4387-90. PubMed ID: 22331187
[TBL] [Abstract][Full Text] [Related]
30. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
31. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
[TBL] [Abstract][Full Text] [Related]
32. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
Diaz-Pallares C; Lee H; Luider J; Duggan P; Neri P; Tay J; MacCulloch S; Bahlis NJ; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):394-399. PubMed ID: 32146104
[TBL] [Abstract][Full Text] [Related]
33. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
[TBL] [Abstract][Full Text] [Related]
34. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA
Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.
Landau H; Hassoun H; Rosenzweig MA; Maurer M; Liu J; Flombaum C; Bello C; Hoover E; Riedel E; Giralt S; Comenzo RL
Leukemia; 2013 Apr; 27(4):823-8. PubMed ID: 23014566
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis.
Liu B; Wang Y; Ning X; Bai M; Wang D; Zhao J; Zhou M; Sun S
Curr Probl Cancer; 2021 Apr; 45(2):100669. PubMed ID: 33127168
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Tessenow H; Holzvogt M; Holzvogt B; Andrea M; Heyn S; Schliwa T; Schwarz M; Zehrfeld T; Becker C; Pfrepper C; Franke GN; Krahl R; Jentzsch M; Leiblein S; Schwind S; Bill M; Vucinic V; Lange T; Niederwieser D; Pönisch W
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2049-2058. PubMed ID: 28534173
[TBL] [Abstract][Full Text] [Related]
38. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of primary systemic amyloidosis with the combination of bortezomib and dexamethasone].
Zhai YP; Liu HN; Yu YP; Zhou XG; Song P; Li F; Wang XW
Zhonghua Xue Ye Xue Za Zhi; 2010 May; 31(5):319-22. PubMed ID: 21122311
[TBL] [Abstract][Full Text] [Related]
40. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.
Palladini G; Milani P; Foli A; Vidus Rosin M; Basset M; Lavatelli F; Nuvolone M; Obici L; Perlini S; Merlini G
Leukemia; 2014 Dec; 28(12):2311-6. PubMed ID: 25059496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]